Sihoon Lee

Prof. Dr. Sihoon Lee

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 May 2017 in Clinical Endocrinology
Verified
Journal Article
Closed access
PDF file
SPSo Young Park
So Young Park
SPSe Eun Park
Se Eun Park
SJSang Won Jung
Sang Won Jung
HJHyun-Seok Jin
Hyun-Seok Jin
IPIe Byung Park
Ie Byung Park
SLSihoon Lee
Sihoon Lee

1 January 2016 in Journal of Korean Medical Science
Verified
Journal Article
Open access
PDF file
SLSihoon Lee
Sihoon Lee
SPSo Young Park
So Young Park
HKHyun Jin Kwon
Hyun Jin Kwon
CLChul-Ho Lee
Chul-Ho Lee
OKOk-Hwa Kim
Ok-Hwa Kim
YRYumie Rhee
Yumie Rhee
Lee S, et al. J Korean Med Sci. 2016 May;31(5):735-742. https://doi.org/10.3346/jkms.2016.31.5.735

19 March 2020 in Endocrinology and Metabolism
Verified
Journal Article
Open access
JLJoon-Hyop Lee
Joon-Hyop Lee
DMDavaatseren Munkhtugs
Davaatseren Munkhtugs
SLSihoon Lee
Sihoon Lee
Since parathyroid hormone (PTH) was first isolated and its gene (PTH) was sequenced, only eight PTH mutations have been discovered. The C18R mutation in PTH, discovered in 1990, was the first to be reported. This autosomal dominant mutation induces endoplasmic reticulum stress and subsequent apoptosis in parathyroid cells. The next mutation, which was reported in 1992, is associated with exon skipping. The substitution of G with C in the first nucleotide of the second intron results in the exclusion of the second exon; since this exon includes the initiation codon, translation initiation is prevented. An S23P mutation and an S23X mutation at the same residue were reported in 1999 and 2012, respectively. Both mutations resulted in hypoparathyroidism. In 2008, a somatic R83X mutation was detected in a parathyroid adenoma tissue sample collected from a patient with hyperparathyroidism. In 2013, a heterozygous p.Met1_Asp6del mutation was incidentally discovered in a case-control study. Two years later, the R56C mutation was reported; this is the only reported hypoparathyroidism-causing mutation in the mature bioactive part of PTH. In 2017, another heterozygous mutation, M14K, was detected. The discovery of these eight mutations in the PTH gene has provided insights into its function and broadened our understanding of the molecular mechanisms underlying mutation progression. Further attempts to detect other such mutations will help elucidate the functions of PTH in a more sophisticated manner.

24 December 2019 in JAMA
Verified
Journal Article
Open access
PDF file
SASong Vogue Ahn
Song Vogue Ahn
JLJoon-Hyop Lee
Joon-Hyop Lee
EBErin Allana Bove-Fenderson
Erin Allana Bove-Fenderson
SPSo Young Park
So Young Park
MMMichael Mannstadt
Michael Mannstadt
SLSihoon Lee
Sihoon Lee
In 1999, the South Korean government initiated a national cancer screening program, which led to increased high-resolution ultrasonography screening for thyroid cancer. Consequently, thyroid cancer incidence increased from 7.2 per 100 000 population in 1999 to 68.7 per 100 000 population in 2011,1,2 and most patients received surgery. However, many screen-detected cancers were small and likely indolent. Concerns about overdiagnosis were raised beginning in 2012, and ultrasonographic screening was discouraged in 2014, leading to decreased incidence of thyroid cancer and thyroidectomies.3,4 We assessed the changes in incidence rates of postoperative hypoparathyroidism, a complication of thyroidectomy, between 2007 and 2016.

18 January 2022 in Frontiers in Endocrinology
Verified
Journal Article
Open access
KLKyu Won Lee
Kyu Won Lee
YSYoochan Shin
Yoochan Shin
SLSungahn Lee
Sungahn Lee
SLSihoon Lee
Sihoon Lee
Consistent activation and functioning of thyroid hormones are essential to the human body as a whole, especially in controlling the metabolic rate of all organs and systems. Impaired sensitivity to thyroid hormones describes any process that interferes with the effectiveness of thyroid hormones. The genetic origin of inherited thyroid hormone defects and the investigation of genetic defects upon the processing of thyroid hormones are of utmost importance. Impaired sensitivity to thyroid hormone can be categorized into three conditions: thyroid hormone cell membrane transport defect (THCMTD), thyroid hormone metabolism defect (THMD), and thyroid hormone action defect (THAD). THMD is caused by defects in the synthesis and processing of deiodinases that convert the prohormone thyroxine (T4) to the active hormone triiodothyronine (T3). Deiodinase, a selenoprotein, requires unique translation machinery that is collectively composed of the selenocysteine (Sec) insertion sequence (SECIS) elements, Sec-insertion sequence-binding protein 2 (SECISBP2), Sec-specific eukaryotic elongation factor (EEFSEC), and Sec-specific tRNA (TRU-TCA1-1), which leads to the recognition of the UGA codon as a Sec codon for translation into the growing polypeptide. In addition, THMD could be expanded to the defects of enzymes that are involved in thyroid hormone conjugation, such as glucuronidation and sulphation. Paucity of inherited disorders in this category leaves them beyond the scope of this review. This review attempts to specifically explore the genomic causes and effects that result in a significant deficiency of T3 hormones due to inadequate function of deiodinases. Moreover, along withSECISBP2,TRU-TCA1-1, and deiodinase type-1 (DIO1) mutations, this review describes the variants inDIO2single nucleotide polymorphism (SNP) and thyroid stimulating hormone receptor (TSHR) that result in the reduced activity of DIO2 and subsequent abnormal conversion of T3 from T4. Finally, this review provides additional insight into the general functionality of selenium supplementation and T3/T4 combination treatment in patients with hypothyroidism, suggesting the steps that need to be taken in the future.

4 July 2018 in Scientific Reports
Verified
Journal Article
Open access
PDF file
Eunkuk ParkEunkuk Park
Eunkuk Park
JJJaehoon Jung
Jaehoon Jung
OAOsamu Araki
Osamu Araki
KTKatsuhiko Tsunekawa
Katsuhiko Tsunekawa
SPSo Young Park
So Young Park
SLSihoon Lee
Sihoon Lee
Deiodinase 2 (DIO2) plays an important role in thyroid hormone metabolism and its regulation. However, molecular mechanism that regulates DIO2 activity remains unclear; only mutaions in selenocysteine insertion sequence binding protein 2 and selenocysteine tranfer RNA (tRNA[Ser]Sec) are reported to result in decreased DIO2 activity. Two patients with clinical evidence of abnormal thyroid hormone metabolism were identified and found to have TSHR mutations as well as DIO2 T92A single nucleotide polymorphism (SNP). Primary-cultured fibroblasts from one patient present a high level of basal DIO2 enzymatic activity, possibly due to compensation by augmented DIO2 expression. However, this high enzymatic active state yet fails to respond to accelerating TSH. Consequently, TSHR mutations along with DIO2 T92A SNP (“double hit”) may lead to a significant reduction in DIO2 activity stimulated by TSH, and thereby may have clinical relevance in a select population of hypothyroidism patients who might benefit from a T3/T4 combination therapy.